2024
Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights
Honhar P, Sadabad F, Tinaz S, Gallezot J, Dias M, Naganawa M, Yang Y, Henry S, Hillmer A, Gao H, Najafzadeh S, Comley R, Nabulsi N, Huang Y, Finnema S, Carson R, Matuskey D. Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights. Brain Communications 2024, 6: fcae345. PMID: 39429243, PMCID: PMC11487911, DOI: 10.1093/braincomms/fcae345.Peer-Reviewed Original ResearchDAT availabilityMotor severitySubstantia nigraDopamine transporter availabilityClinical trials of Parkinson's diseaseParkinson's diseaseLongitudinal studyTracking longitudinal changesClinical correlatesVentral striatumTransporter availabilityNigrostriatal regionParkinson's disease patientsPutamenMotor severity scoresAssociated with increasesSubstantiaDATLongitudinal changesTremor scoreNegative associationNigraSubstantia nigra of Parkinson's disease patientsTremor severityPET biomarkers
2018
Semiquantitative Analysis of Dopamine Transporter Scans in Patients With Parkinson Disease
Tinaz S, Chow C, Kuo PH, Krupinski EA, Blumenfeld H, Louis ED, Zubal G. Semiquantitative Analysis of Dopamine Transporter Scans in Patients With Parkinson Disease. Clinical Nuclear Medicine 2018, 43: e1-e7. PMID: 29112012, PMCID: PMC7257254, DOI: 10.1097/rlu.0000000000001885.Peer-Reviewed Original ResearchConceptsStriatal binding ratiosDAT scanParkinson's diseaseParkinson's Progression Markers Initiative (PPMI) databaseDopamine transporter imagingDopamine transporter scanAdjunct diagnostic toolBinding ratioOutpatient cohortPPMI cohortTransporter imagingParkinsonian disordersMotor severityHealthy controlsClinical measuresStriatal regionsVisual readsTest cohortTest patientsSignificant negative correlationPatientsPPMI databaseDiagnostic aidCohortTraining group